Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623099 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
A Phase 4 study of Anxiety, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 132
- Enrollment target
- 1
- Study location
NCT04623099 is a Phase 4 study of Anxiety that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 132 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04623099, a Phase 4 study of Anxiety, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 132 participants
- Enrollment target
- 1
- Study location
Study Summary
This double-blind, 12-week study will consist include132 anxious youth who are randomized (1:1) to standard or pharmacogenetically-guided escitalopram dosing. Block randomization (1:1) will be stratified by sex and metabolizer status.
Conditions Studied
Interventions
- DRUG Escitalopram
Study Locations (1)
Ohio
- University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04623099
The ClinicalTrials.gov registry entry for NCT04623099 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (70% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which Escitalopram is the first listed.
NCT04623099 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04623099 about?
NCT04623099 is a clinical study titled "Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)". This double-blind, 12-week study will consist include132 anxious youth who are randomized (1:1) to standard or pharmacogenetically-guided escitalopram dosing. Block randomization (1:1) will be stratified by sex and metabolizer status.
What is the current status of trial NCT04623099?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 132 participants. The study started on 2021-03-08. Estimated completion is 2026-12-01.
What conditions does trial NCT04623099 study?
This clinical trial studies the following conditions: Anxiety.
What interventions are being tested in trial NCT04623099?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT04623099?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04623099 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
RECRUITING · Phase 4
-
Brain Stimulation & Generalized Anxiety Study
ACTIVE NOT RECRUITING · Phase 4
-
Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting
COMPLETED · Phase 4
-
Epidiolex® for Anxiety in Pediatric Epilepsy
COMPLETED · Phase 4
-
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.